Exploration demonstrates improved therapeutic potential of naringenin in breast cancer, indicating a novel approach to treatment.
Breast cancer remains the second leading cause of cancer-related deaths worldwide, with mortality rates continuing to rise annually. While conventional treatments, such as surgery, chemotherapy, and radiotherapy, are available, they are not 100% effective and often damage healthy tissues, negatively impacting patients' quality of life. Naringenin, a promising phytonutrient, has demonstrated anti-cancer properties through various mechanisms that inactivate carcinogens. However, its therapeutic potential is limited by poor bioavailability and hydrophobic nature. Nanocarrier-based drug delivery systems, an application of nanotechnology, offer a promising solution to overcome these limitations. These systems enhance the solubility, circulatory half-life, and biodistribution of bioactive compounds like naringenin while reducing side effects. This innovative approach shows significant potential in improving breast cancer treatment outcomes.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: